Registered number: N1070062
IIMRC Charity niimber: XT5406
Charity Commission (Northern Ireland) number: NICIOS839
The Mcclay Foundation
(a company limited by guarantee)
Annual report and financial statements
for the year ended 30 September 2023

The Mcclay Foundation
(a company limited by guarantee)
Annual report and financial statements for the year ended 30 September 2023
Refcrence and admini.8trative details of the Charity
Chairman's rcport
Trustees, repoit (incorporating the direclor, s rcport)
3- 14
Independent auditoi's, report to the members of 'l"he Mcclay Foundation
15- 17
Statement of financial activities (incorporating income and cxpenditure account)
18
Balance sheet
19
Cash flow statement
20
Notes to the financial statenients

The Mcclay Foundation
(a company limited by guarantee)
Reference and administrative details of the Charity
TrusteeslDirectors
Company secretary
A l) Anmstrong
T Scott
The Mcclay Foundation Lorporate l i'ustcL l.imited
(Directors listed below)
A D Armslroiig
S Lampbell
J Irvine
C Ilayburn (resigned l Jaiiuary 2023)
I Iluddleston
P Diainond
D Llements
11 £t¢v¢n%on
,: McAllistei'
N Flarkin
K Stephens
G McBurney (appointed l October 2022)
C Ilayburn (resigned l January 2023)
Ilegistered officelPrincipal offlce
Banker5
Altna¢ I louse
20 Seagoe Industrial 14.slate
Craigavon
BT63 5QD
Danske Bank
Don¢gall Square West
Beltast
BTI 6JS
Independent auditors
HMRC Charity number
Pricewaterhou5eCoopers l.l.P
Chiiriered Accountants and Statutory Auditors
Merchant Sqiiarc
20-22 Wellington Place
Belfast
13TI 6Gt.t
XT5406
Charity commission (Northern Ireland)
number
NIC105839
Solicitors
3DB Pilmans Solicitors
()ne Barlholomcw Close
l.ondon
F.C I A 7BL.
Registered numbcr
N1070062

The Mcclay Foundation
(a company limited by guarantee)
Chairman's report for the year ended 30 September 2023
The Mcclay Foundation has Tecently prepai'ed a new five-year strategic plan (2022-2027) to follow th¢ previous plan agi'eed
by the Trustees in 2016.
'rhe Trustee% have identified four sli'ategiic areas of foeus".
Innovatioii Research a¥Jd developinent of new m¢dicin¢s.
Oncology res¢arch- targ¢ts and bioinarkei's.
Digniiy and Compassion Research led care for those in end of life, or l ife limited circuinstances.
Ilealth and Wellbeing - Activities to promote health and w¢llbLing in disenfranchised communiti¢s and gcograpliical
areas in the developed and the developing world.
This report illu%trates the work we have done this year to dcihonstrilte oiir long-lerm commitinent to the principal objectives of
I'he Mcclay Fouiidalion and oui. desii-e to iipholil Sir Alleii Mcclay's wishes by continuing his legacy and vision to Inake a
iiicaii ingful conli-ibulion to l)uinan hLalth and WLllbeing, worldwide.
The work of ihe M¢Clay Foundation in the year ended 30 .%epieniber 2023, working with Inany and varied partners to achieve
its aims and objectives, has resulted in significant and measurable bcnefit to ihe health and wellbcilig of niany in society.
Alan Annsti'ong
Chairman
I￿ J %JL4

The Mcclay Foundation
(a company limited by guarantee)
Trustees, report for the year ended 30 September 2023 (incorporating the Director's
report)
The Tiu.4tee8, who are also directors of the charitable company for tl)e purpose of the Companies Act 2006. pres¢nt their
Annual reijoit and the audited financial statements for the year ended 30 September 2023. This report coI)stilutcs tlie Trustees,
Report required under the Companies Act 2006 and thL' C,haritlLS Act (Nortlien] Ireland) 2008.
The 'frLislees liave adopted the provisions of the Companies Act 2006 and Accounting aiid Repoi'ting by Cliarities.. Stateinent
of ReLoTnmeiided Practice applicable to charities pi'eparing their financial slateinents in accordancc with the financial
Reportiiig Standard applicable in the UK and R¢publi¢ of Ireland (P'RS 102) effective l January 2015 {Charilies SORP
(FR.8 102)). iii preparing tlie Annual report and financial stale111ent5 of the charity.
Reference and administrative details of the charity, the Trustees, and adviso
The Trustees of the charity are listed on page l. The principal and regi8tered office of the charity is also listed on page I
together witl) details of th¢ profcs8iunal advisers and bankers.
Structure9 governance and management
I'he Mcclay l.oiindation ("Ihe charity" or"Ihe Foundation") was inCo￿Oraled as a company liinited by guarantee on 31
July 2008. Tlie coini)any is exempt ui)der this legislalion froim using "limited" as part of its name. It does not liave a sliaie
capital and the liability of each inember to Contribute lo the assets of ihe company is liniited to £1 . The charity registercd
with the Charity Commission in Northern Ireland on 22 June 2019, registration numb¢r NIC105839.
The charity is registered with the Coinpanies Regislrar registration nuinber N1070062. It is also recognised as a charity by IIM
Revenue and Customs ("EIMRC"). XT5406.
Governance
The role of the Tn15tees is to ensure that the cliarity is effeclively governed. to ensure thai the charity complies with all
relevant legislation, ils own Articles of Associatioii and the requirements of good practice- and 10 ensure that the Charity works
to agreed strategic and operational plans.
Tl)e cliarity's governing doculneiils are the Articles of Associatioij (as amend¢d iii 2018) which assist tlie Ti'ustees in the
Inanagemenl of the charity.
The Aiticle5 of Association i'equir¢ tliat a Trustee sliall hold office until the ¢nd of the Annual General Meeting held nearest in
tiine to Ilie third anniv¢rsary of his el¢Ltion. One third or the nearest to onc thii-d, of "fnist¢es must relii'e at each Ai)iiual
General Meeting, thos¢ longest in office retiring first. A Trustee retiring by i-otation shall be eligible for re-election. This is
approved by a majority Vote by the Trustees at the Annual General M¢¢ling (in their capaciiy as coitjpany imembers). Tlie
Foundation ensures all ils Truslee% are trained under the various regulations.
Risk management
Tl)e I ruslees have actively reviewed tl)e major risks, busiii¢ss and operalioiial. that tlie cliarity Inay t.acc and coiifirm that systems
have been establislied to miligate SI￿77r]cant i'isks,
Appointment of new Trustees
New Trustee5 are i'ecruiled by open recruitinent by existing T￿slee5 to fulfil specific role8 on the Board. T]ic potential trustee
is then intei'viewed by Ihe Board I'egdrding their willingness to beconie a tru%lLe and their poieiitial contribution lo IhL
J.oiindation is considei'ed.
Policy for tlie awarding of granls
11)e Fouiidation's grant progr￿1]ineS are approved by I rustees. All prograinmes involve an applicatioii proce.ss. Applicaiions
are assessed by tlie I nistees, including robu.%t Hk8essnicnt of guvernance. l.'inal approval is sought at boai'd Imcetings before
decisions are .shared ivith applicai)Is. l-he applicants must sign lip to Tenns & Conditions before funding is i-elcased Vid bacs
payinent. All tyranlees must complete an ¢valuation r¢port, outlining expenditure, perforiiiaiic¢, and iinpact on at least an
dl)nual basi5.

The Mcclay Foundation
(a company limited by guarantee)
Trustees, report for the year ended 30 September 2023 (incorporating the Director's
report) (continued)
Objectives and activities
Our Vision- To make ineaningful iinproveinent and advanceinent in human Iiealth.
Our Mission - To support those involved in advancinLY biomedi¢al res¢ai'ch, huinaii healih, and wellbeing around the world.
Tlie objeclive5 of the charily as laid out in tlie Charity's governing docuinents are..
the relief of poverty, unemployment and financial hardsliip by the &yeneration and promotion of etnployment
opportunities for the people of Northern Ireland-
the advancement of health and healthcare by the support and encouragement of research and innovdtion in the field of
healthcare and allied iechnologics
the advanceinent ofthe health and wellbeing of all people and specifically thos¢ in poor coinmunities to enable thein
to access and benefit from the latest advances in healthcare.
tlie prevention, control, and ciire ofdisease by advaJicing the use of diagnosiic tools and driigs: and
to support and proinote such educational purposes as the .5 rustees shall select, provided alway% that such purposes
sha51 be exclusively charitable in law.
(iuidin
Priii¢i
les
The Trustees of the Foundalion have agreed to the following guiding principlcs to enable the Foundation to achieve its
charitable purposes,
The Foundation will pursue strategic activitie5 which deinonstrate:
Meaningful support that will enable tl)e organisation andlor projcct to advance its objectives significantly and,
5imullaneously, advance the charilabl¢ purposes of ihe Foundation.
A benefit that would not othenvise have been realised by th¢ organisation, but for the support provided.
Support for Nl based organisations and/ or pi'ojects, where possible.
The main aclivities undertaken in relation to these objcctives are outlined wiihin the achievements and pcrfonnance section.
1'1ie F oundation's activities do not include social investmenl or tl)e engagemeE)t of volunteers to nieet the foundation's
¢haritable objectives,
Aehievemellts and Performance
Strate
ic F ocus Areas
Thc Trustees have agreed to apply these guiding principles to the following strategic area5:
l. Innovalioii - Research and development of new medicinls.
2. Oncology research . . I"arg¢ts and bioiDarkers.
3. 1)ignity and Conipassioii - Res¢ar¢h led care for those in end of life, or life limited cirLuinstaiices.
4. FIealth and Wellbeing Aetivities to promote health and wellbeing in disenfrallchised com]￿UnitI¢S and geographical
areas in tl)e developcd and Ihe developing ivoi'ld.
I. Ip7novalion - Re.sLarch and DevL?lo
Inenl o
NL?i¥ Medicines
'riie l.-oundation liold own5 tlie Alinac Group ('"Almac" or'thc Cjroup") and Inoi)ilors the activities ofthe (iruup Lnsuring it
adhei'es to, and delivers on, tlie cliaritable objectives of the l oundalion.
'I'he overriding obJectiv¢s of Almac ar¢ to..
adliere to and dL'liver on 11)e charilable objectives of 'lhe McLlay I,'oundatioii
ultimately benefit the wellbeing olpatients throutsh the I'esearch and developmeiit of n¢w Inedi¢iii¢s; und
dcvelop and expand a world class Group of conipanies operating In the Ph￿IllaCeUtICal and Biotech sectors.

The Mcclay Voundation
(a company limited by guarantee)
Trustees, report for the year ended 30 September 2023 (incorporating the Director's
report) (continued)
l. Jnnovation - Re.geurch and Dei?elo
menl o
New Medicines
ontiniied
-riiereby advancing Sir Allen Mcclay's legacy and liis vision for 'fhe Mcclay Foundation lind its charitable purposes,
Almac's Strategic Goals include:
reinaining privately owiied by l-hL Mcclay I'"oundation'
continuing Group wide innovation.
achieving bes1-in-Llass bu8iness offerings-
cultivating a desirable place to work.
¢nabliiig the latest healthcare advances to be available to all-
continuing the gencratioii of employinent opportuniti¢,s and providing skills training for the people of Northern
Ireland. and
maintaining and iinproving profit margins to incrcase the ainount available for reinv¢stinent into the work of Ili¢
Almac CJroup l.imited and, by extensTon. the charitable objectives of The Mcclay Foundation.
Aetivities and Impaet
Almac Cyroup
The Alinac Group is an established contract development and maniifactliring organisation
which provides an cxtensive range of integrated service5 acr055 the drug developnienl lifecycle
lo the phannaceutical and biotech sectors globally. Tlie Almac Group has continiied to grow ils
einployee base lo approximately 7,000 people and hds contributed lo over 700/0 of US Food and
Drug Adiniiiistration (F DA) approved new moleLular entities (NME5) in the last 3-year period
as the Group coiitinues lo work with all lh¢ top 2.5 BioPliarma COTnpanies globally in the
developnient of new medicines.
The Alinac Group is eomprised of a number of busin¢8s units. each of whicli contribiites to Ihe
advaticemei)t of Alrnac's Strdlegic Goals and lo ihc r¢.%earch and (ievelopmetst of new
medicines.
Almac Discovery is an independent, res¢ar¢h driven dnig discovery company, dedicated to the
devul<)PlllLlIt of novel Rnd innovative Ih¢rapeutics.
Alniac ScienLe% provides integrated serviLes froin dLvelopment to cominercial scale
maniifdLlurL ()fadvanced ii)lermLdiates and Active Ph(Irmaceiitical Ingredienls (API). Almac
SLiLllLL'% pr()vidLts d ranbYL nf 4LrviLLS for sinall 11)olecules and peptides and appli¢s iniiovative
biocatalysis and technology solutions which contribute to cost and time savings for ils ¢lienls,
Almac PhArma Serviees provides expert pharmaceutical drug product developl￿ent aiid
i)ianufacturin&i soliilions, supporting all phases of ¢lini¢al trials, Ihrough product launch aiid
ongoing supply.
Almac Dlagnostics Strvices is a global stratified medicine company splcialising in biomarker
driveii cliE)ical Irialg. Almac Diagnostics S¢rvice.s is foeiised on tl)e discovery, developincnt and
coininereialisation of diagnostic and Companion diagnostic tests.
Almae Clinical Serviee5 is recognised as an innovative, globAI solutions pi-ovidei- within the
specialised and coinplex markel of Clinical Érial %upply. Alinac Clii)ical Services, integrated and
#daptable 501utioiis offer the inost flLxible approacli to support tlie delivery ofglobal ¢lini¢¢il
trials from protocol right through to patient delivery.
Alma¢ Clinical Technologies is a global provider of Interactive ResponsL Technology (IRT} aiid
expert con.sullaiicy for the biophamiaceutical industry. empowei'ing clinical trial sponsors to piY>-
aclively manage siles, paliejits, and clinical supplies througjh our indu51ry'.leadiiig technology
s()Iiitions.
Galen develops, Inarkets and s¢lls a wide range of branded and genertc pharinaceuticals tuid
nedical nutrition
roducts.

The Mcclay Foundation
(a company limited by guarantee)
Trustees, report for the year ended 30 September 2023 (incorporating the Director's
report) (continued)
Almac Group
(continued)
From a retsearch and devclopment perspective, companies wiihiii th¢ (Jroup have b¢en eiigag¢d
in the following actiwities ovcr the pa%t 12 Inontlis-
Alinac Discovery's potei)t Wee l iiihibitoi. moved into Clinical Phu,%e
Almac Discovery's AKT inliibitor Illoved into Clinical Phase
Almac Discovery performed extensive work on DIJB targets and Pi-olein l)rug
Conjugate5
Alinac Sciences grew its neo peptide busii)ess, thus Lnabling ils customers to develop
personalised cancer vacciii¢s. Alinac Science5 has Inaniifactured >12,000 peptides for
approxiinately l 00 patienls and 6 clients.
Alinac Sciences developed, manufactured and supplied 2 m¢ti'i¢ tonnes of a kLy
ingredients (an iMmobTlised enzyme) for use in a product used to treat paediati'ic patients
and aduli palients with short bowel syndroine.
AITnac Pharina Services supported phann<iceutical developrnent activities for 108 new
drugs and supplied clinical Irial material for 58 of these iiew drugs. Thei'apeutic areas
supported include oncology (breast and ovarian cancer), FIIV-I {Fluman
Immunodeficiency Virus type-l) and Parkinson Disease.
Almac Phanna Services Iiianufactured registration batches for 6 new products (includit]g
in the therapeutic areas of cystic fibrosis and immunodeficiLncy), launclied 8 new
products. launcl)ed 73 new coiMm¢i'cial SKUS (including in the therapcutic areas of
oncolo&'y, neurology and infectioiis diseases) and supported the supply of 4 Advanced
'rherapy Medicinal Products through ultrd-low temperature packaging, labelling and
distribiition.
Alinac Diagnostic lervices inv¢%teLI in the construction of a new 40,000 sqft diagnostics
developiment and iiianufacturing facility. Tl)is new facility will ensure 11181 Alinac
Diagnostic Services reinains at the forefront of developing new genomic tests io
facilitate the genetic screening of patients to personalise thcir treatment.
Alinac Dia£nosti¢% invested in a new I Ilumina Novaseq X instrument for huiiian genotne
sequencing. Tliis new instrlimenl will allow Almac Diagnostic Services to substantially
scalc up the nuinber of patients samples tliat can be serL'ened for individual disea5e-
ca115ing mutations.
Alinac Clinical Services expanded its manag¢d access program (MAP) services:
ensuring that paticnls completing a clinical trial have posl-trial access to unlicenscd
medicines. Almac Clinical Services now has ov¢r 134 managed access prograins
glob<illy.
Alniac Clinical Technologies expuiided it8 leadership position in Ilie support of coimplex
innovative clinical trial designs (CIDS). CID8 ¢nsurc' tl)at f¢wer patients receive
iiieffective treatments, thus reducing developinent costs and brining new treatments to
Inarket faster. Aliiiac Cliiiical 'feclinologies' biostati%tical coiisultants are tlioughi
leaders in this space and have partnered witli Inultiple coirpaiiies to dL't¢rmin¢ the best
way to impleiiient these designs by levtrirt8 ACT'S proprietary Jnteractive Response
I'echnoloEY Systeiii (IXRS@).

The Mcclay Foundation
(a company limited by guarantee)
Trustees, report for the year ended 30 September 2023 (incorporating the Direetor's
report) (continued)
Alm¥c Group
(continued)
In the last 12 months Almac ha8 maintained 105 granted patents with a further 80 pendlng
approval. 1'I)ese include the following:
Alinac Discovery- DUB inhibÈto¥s (including USPI 9), Protein Drug Conjugates
(including ROR I ). PNIJ Payload8 and l.oop l.ibraiy Variants.
Alinac Diagnostic.%- DDRD assay (prostate caiicer), MEK {cancer signalling)
Almac continues to collaborate with academia and other gylobal instttutions to deepeii its
existing knowledge and skills in specific (trea5. Ulilising the additional resource, dala. and
insighl available through Ihese paitnei-ships enables Almac lo Continue to deliver Group wide
innovaiion and progress ils R&D activity ¢ffe¢tively. F.xaiiiples include the following..
Ilelinholt7 Res¢arch C¢nlre Miinich (DU13 inhibilors)
El¢ismogenlAberdecn University {ROR- I cell surface receptor)
S-LORT (Oxford University & others - t)DRD Assaylcolorectal cancer)
2. Oncolo
Re.¥earch - Tar
els and Biomai'kers
Str8teglc Aim5
l. To create and sustain a world class research infraslruccure and culiure in Northem Ireland to advance current research
practice and procedures in oncology gl()bally.
2. To Choose and appoint leaders with academiclindustrial cxperience to inspire and drive relevant and ineaningful
research.
3. To develop novel and strategic approachcs to personalised cancer trealment wilh greater potential benefits ov¢rall.
Activities and Impact
QUB-£151,040
Professors Richard KeThnedy and I'im Ilarrison continvod their research in their capacities as
Mcclay Chair in Medical Oncology and M¢diciiial Cliemistry respectively at Queen's
University Belfast ("QUB"),
Professor Tim Harrison - Mccla
Chasr in Medirinal Chemistr
Research
Working with Prof. Dan I,ongley and Ip5cn Pharma on developiiient of First in Class J."I,IP
inhibitors following out-li¢cnsing of tliis QUB derived programme to Ipscn in Novcinber 2022.
I'h¢r¢ is the potential for Ihe ri,Ip inhibilor5 that are being developed to beLonie %lHndard-of-care
a(Fents 111 several cancer5 With iznplication5 for the clinical Inanagement of these ¢anccr5. 1.his
will most likely be based on a coinbination rcgimcn, although ihei'e is the potential for single
agent adlliinistrdtion in Inolecularly defined subgroups of palienls. l."I,IP inhibitors also have the
potential to re-sensitise tuInours that have becoine resistant to slandard of cal'e therapies. There is
the potential for these P"ir5t in Class inhibitors to providc new and iinproved Ireatinent OPlion5 for
caiicer patieiits, wl)ich aligns ivith Tlie Mcclay Foundation's objeclivcs.13ased on the biology of
FI.IP, following clinical proof of concept in cancer paliei)ts, the coii)pounds may also have further
utility in indicaliuns b¢yond cancer.

The Mcclay Foundation
(a company limited by guarantee)
Trustees, report for the year ended 30 September 2023 (incorporating the Director's
report) (continued)
QUB-£151,040
(continucd)
Publications
Author or inveiitor on >145 publicalions? patents and paleiit applications. Most recently..
RAI.B CyTPase: a critical re
ulatoi. of DR5 ex
ression and TRAII. sensitivi
in KRAS mutant
colorectal canc¢r Khawaja, I lajrah. Campbell, Aiidrew; Roberts, Jainie /,.. Javadi, AriMan-
O'Reilly, Paul; M¢Art, DaiTagh; Allen, Wendy l.. Majkut, Joanna- Rehin, Markus. 13ardelli,
Alberto; el al. Cell Death & Disease (2022), 11 {10), 930.
Pagc, N., Wappett, M., O'Dowd, C.R. cjl al. Ideiitification and developinent of a subtype-
selective allosteric AKT inhibitor siiilable for clinical developinent. ,gci Rep 12, 15715 (2023).
https:Ildoi.orgllO.10381s41598-022-20208-5
Talks and Teaehiiig
SCI Online lecture series: Invited lectur¢.' Ventures in New Target Space: Drugging the
DUBS- Oct 2022
Translational ReseAreh: froin Concept to Commerci21is8tion (MRF.S) Teaching. QUB.
October 2023 . 1.ecture'. Jhe Drug Discovery aiid Developi)Jent Process
SSC Module in Translatlonal Medicine"From Bench lo Bedside and Back>* Teaching
for 2nd year iTr¢dical 5tudenls, October 2022 - I,ecture: Drug Discovery
Career5 Talk, QUB PostgraduAte Studeiits,"Careers in the Pharniaccutical Industry" May
2023
Grants:
Small molecule inhibitors of ihe anti-apoptolic protein ri.lp for the treatsnent of cancer,
Wellcome I"rusl Seeding Drug Discovery Award, 2015, £5,600,000 - 4-year progyaiiinie
indepLndent of Alinac (co-Pl)
June 2019 - Centre of l=.xcellence for Ubiquitin Drug Discovery, £5.1 M liivest Noitheni Ireland
grant (Pl).
BREATII, (Border aiid Ilegions Airways Training Elub) Post-Doctorate Researchcr I
Research I".ellow has funded under the Luropcan lJnion's INI'I.;RRF.G V A Programme (ca.
£IOOK, PI)
Ii)novation Scholar- IUK funded.. working with Prof. Dan l.ongley
Innovation Scliolar- IUK funded: working witli Dr Jam¢s Reihill
Joint Supervisor (with Joanna McCTouran, 'frinity College. Dublin) for 2 year EIE.'A Funded
North Soutli Project: 'Snapsliot'. l arget engagenieiit assays - a radical approach to capture a
snapshot of probe-enryme bii)ding" _ C200K
Lo-Applicani for Nl Strengtl) in Places bid. Future Mediciiies Institute" (£14.5M
programi))¢, pending)
Co-pi for BBSRC"Prosperity Partnership" bid. E4 Stablishment of a Nl Cenli-e of b.xcellence
for Proteomics" (£5.2M pi'ograinine, pending)

The Mcclay Foundation
(a company limited by guarantee)
Trustees, report for the year ended 30 September 2023 (incorporating the Director's
report) (continued)
QUB- £151,040
(continued)
Panel Jnembership:
Panel rneMber- Medical Research Council {MRC) Developmental Palhway Fundriig
Scheme (Dpfs).. Jan2022 -
Panel member- Britlsh Ileart Foundation (BHF), Translation81 Award5 C4bmmiltce.'
Nov 2023-
Panel member.. QUB Research Innovalion and Translation Coiiiinittee
Chair- QUB MRC Fuiider Liaison Grovp (Sept 2022 -present)
Ad-hoc member of MATRIX panel- reviewed Nl Cily Deal and Strength iii Places bids
PhD Supervisor for 4 PhD Student8
TACT Marie Curie l.iTN.. Joint PhD sup¢rvisor for Thoinas Favrdud, 3-year progrEunJne (with G
Cotton)
Joint PhD Supervisor (with Simon McDad¢) for Mark Wappett: Mark is undertaking a PhD
by publication in bioinfoni)atics. This is a fiist of its kind at QUB and will provide a
blueprint for others wlio want to follow this route.
PhD Supervisor for l.auren Proctor.. Lauren is undcitaking a part time PhD in medicinal
cheinisiry at QUB whilst working at Almac Discovery
PhD Supervisor for Patrick Preston (joint with K Savage)-_ DfE funded 3-year studentship
"Understanding the role of ubiquitinatioi) on STING-medialed immune regulation following
DNA damage"
Charitable Colltributions
Board member: W5, Odyssey Trust: W5 is an award-winning interactive science and
discovery cenli'e based al the Odyssey, Belfast. As a charitable orgaiiisation, ils Inission is to
proinole science and technology to children and their parents. W5 is one of 5 scieiice centres
who in Augusl 2017 wei'e awarded a sliare of £13M from Wellcome Ti'ust113E". IS Iiispiring
Science Fund following a successful competition bid,
Prof¢550r Ilichard Kenned Mccla
Chair in Medical Oncolo
Research/Scholarshi
2022-2023
C.o-princiiJal ii)vesligalor for the Stratified M¢diLine Cjroup al Queen's University Belfast,
rocussing on Ilioi￿arker discovery and development to guid¢ i)Ircision rnediciiie
6 published peer i'evTewed papers (in Clinical Cancer R¢searcli. Cell Death Discase, Caiicers,
Science Reports, NPJ Breast Cancer, Cornputational Structural Biotechn(ylogy)
(irants:
Co-applicant on Belfast l-Reach bid £5.OM
2. Co-applicant on Northern Ireland Slrength in Place% Seedcorii £50K
Co-applicant on Wellcom¢ Trust ¢-Fl.IP sludy £50K
4. Co-applicant Nl CR-UK I."CMC Centre.. £l.OM
5. Co-applicant on Stren&)th in Places Future Medicine ln51itiite £5.OM (pending)
Chair of R¢scarch Loininittc¢ coniini%sioned by Dept of F.conoiiiy to establish Nl l.ile and
Ilealth Sci¢nces I",co.%ystLm around Ciiy and Regior]al Growth Deals.

The Mcclay Foundation
(a company limited by guarantee)
io
Trustees, report for the year ended 30 September 2023 (incorporating the Director's
report) (continued)
2, C)ncolo
RL'3earch - Tar
ets and Biomai'ker
Lonlinucd
QUB- £151,040
(coiitinued)
Teachin 2022-2023
Tutor 2nd Yeai. SSC Mediciiie"fr()m B¥nch to Bedside"
MI,'D2016 Masters cours¢ l¢¢turer
MRF.S SCM7075 Masters course lecturer
PhD primary sup¢rvisor 3 sludents, secondary 2 students
Supei'vision l Bsc and l Msc Student QUB
Supervision l Msc Student Royal College of Surgeons Dublii)
E."acully Mentor for Icctui'crs; Dr Bob l.adner, Dr Yaser Atlasi, Dr Aid¢n Cole. l)r Sandra
Van Shaebroeck and Dr F.Mma Kerr
Academic Panels 2022-2023
Member of Nl MATRIX panel
Meinber CR-UK New Agents Coinmitlee
Meinber of Nl Lonsortium for COVID-19 Testing
Member of (h¥ Faculiy of Phari?)a¢eulical Medicine Oncology Advisory Board
Member ofNCRI Conference Organising Committee for Nov 2023
Meinber of Patrick G Johnston Cancer Centre Senior Mana
ein¢nÉ Team
3.Di
and C.'om
as&ion - Research Led Care
or Those in fnd o
e Limited Cii"¢umsiances
Strategic Aims
I, To ensure everyone has access to good quality end of life care, regardless of Ihcir circumstances, age, disease, or
culture aiid wherever their place of care.
2, To provide quality of life, positive outcomes, and experiences to those in end-of-life care.
3. 10 provide care and support for life limited children, currently identified as being severely lacking in Northern
Ireland.
4. 1 o support thos¢ oi'ganisations wlio provide holistic care, Iiieeting people's physical, emolional, social, psychological,
aiid spiritual needs, in end of life and life liinitcd circumstanc¢s.
Aetivitses and Impact
Buddy Bear Trust
£ioo,000
Partnering willi the Buddy Bear Trust School in Dungannon whicl) provide8 condiictivc cdiication
and siipport for cliildreii siiflering froin ccrcbral palsy and i)thL'r Inolor (li%oi'dLrs iii siipport of ils
l.if¢tiine of Difference (pliase 2) project.
Nl I lospice
£ioo,000
Siipporting Northem Ii'cland Ilospice as it employs nurses to providL palliative care to patients in
tl)eir own l)oiMes as i)art of tlie hospice's higli-quality, lioli.%tic end-of-life care whicl) enabl¢s
patients lo have the (IPPTopriate support to reinain at home as Ihey approach the end of life.
Lope Cliildrens I'rusl,
known a% Rainbows
IlospicL' for CliildreE] and
Young l)eople
£10,000
Contributed toNvards tlie cost of a 'Sunsliine Coach, to ertablc tl)e l)osptce to facililale day trips
and othei. excursions for childrcn and young people who are seriously ill, and the cost of
iinproveineiits in faiiiily a¢cominodation at the liospice whicli is available to parents when their
cliild or young PLrson is in residencc.
Flolidoy Ilungei. and Get
AclivL £25,000
Supporting Children in Northern Irelaiid (CINI) in ILS 'lloliday Ilunger, and 'GeÈ Active,
Prograinines Kvliich aim to en¥ttage children and young people. ordinarily in receipt of free s¢liool
meals, dui'in(F holiday periods. CINI'S prograiJ)Ines seek iu addiess issues faced by young p¢opI¢
includin
f(iod poverty, ediicalional iinderachieveineni and hcaltli and w'ellness through the
pi'ovision ()f Iiutritious meals, physical activity s¢s%ioiis and learning-based aLtivities.

The Mcclay Foundation
(a company limited by guarantee)
11
Trustees, report for the year ended 30 September 2023 (incorporating the Director's
report) (continued)
3.Di
nil
and C'om
COF21inued
a3&ion - Res'earc'h Led Care
or Thotse in I,ndo
e I.imilLd Cii'L'uni.5'1ance.s'
"riends of Parkview
Special School £2,750
Assisted E,"riends of Purkvlew Special NLeds School in Lisburn, North¢iM Ireland witl) its recent
summer activity scheme.
Friends of the Cancer
L¢ntre £70,000
Supportiiig Friends of the Cancer Centre to fund an additional clinical nurse specialist and also
supporting ils financial grant prograillme which secks to mitigate some of the potcntial financial
in)pacls on paticnls receiving cancer treatment.
Young l.ive5 v Cancer
£25,000
Coiilribuling fiindiiig iowards Young L.ivcs v Cancer's 'Floine from Ilome, project u,liich offers
ac¢oininod¢iLion for parents and siblings close to Belfast City Ilospital and Ihe Royal Belfasl
1108pilrfil for Sick Children, helping lu alleviate tlie addilional fiiianLial burdens of ti'avel,
accominodation and food costs often experienced by faniilies when a young person is receiving
cancer treatment.
4. To Promole Ilealih & Wellbein
in Disen
ranchised (.'ommunilies & Geo
hical Areas
Strategle AIMB
To provide holistic coinmunity-based hcalthcare, empowerment, wellbeing, and education lo disenfranchised
communities, wheth¢r in the developed or developinE world.
2. To foslei. cffective partnerships and collaborate with NCJOS who are providing individuals with healthcare services
and educatioii in disenfraiichised conimunities on a 'bettei' together, basis.
3. To pri)vidL' innovative and responsive solulions to specific health and wellbeing issues in the developing world.
4. l o pi'ovide assistance and 5UPPOrt lo achieve Iiing lasting and significant irliprovement in the hLalih and wellbeing of
those living in poverty.
Activities and Impact
ields of Life
£100,500
Supporting F"ields of Life's l AM CYIRI. initiative, whicli ainis to enjpower girls in F.ast Africa to
coinplete thLir eduLation and to grow into 51rong. healthy young woinen. By constwcting
hy&yiLnic wd.%hrooi)I faLilities al schools, supporting s¢h()ol feeding programmes to encourag¢
%Lhii()I retLntion, and providing training on cliild proleclion and gender eqiiality, l AM (ilRL
seeks to reduce tlie barriers to adole5ceiil girls. and other cliildren's paiticipatioii iii educalioii in
schools and comixunities in E".ast Africa.
Supporting l ields of l.ife's vocational crainiiig institiite scholarsliips to eiiable vulnerable young
people to study courses 5ucli a% building cunstruclion. carpentry; lailoring, fashion and design,.
and cosiiietology, liair and beauty. I'he young people 5UPPOrted by thes¢ scholarships have the
opportunity to learn skills whicli enabl¢ them to secure.jobs, earn a living and have the prospect
of a brighier future.
Plliladelphia Lducatfton
F'.und
£15,658
'I'raii) I'O Be Sinajl
£37,720
Scholarship to as%ist selected student over the tcrin of iheir studies. 'I'he studenl will be chosen
from Unde￿eplesenIed coininunilies in th¢ Phil#delphia Area.
Supporting 'frain 2B Smart in NortliLIM Ireland which seeks lo promote the iinproveinent of
mental health and wellbeing tlirough sport. T'he Poundati<in has provided particular support f(Trr
"rrain 2B Sn]art'.%' projeel co-ordiiialor role and its "#iLssinarttotalk' campaign.

The Mcclay Foundation
(a company limited by guarantee)
12
Trustees, report for the year ended 30 September 2023 (incorporating the Director's
report) (continued)
PublÉc Benefit Assessment
l.or each %trat¢gic Focu8 Area. we will idenlify and monitoi- on an ongoing basis:
The beneficiaries and the effecl of oui. engagement.
I'he pui'pose of our engaLFement.
I"he direct benefi15 which flow fi-oin our chosen purpose.
Ilow the benefits are (or will be) dcmonstrated.
Flow Ilie engagemeiit / benefits fulfil the Foiindation's charitable purposes.
Monitoring
To record the basis of support for any Proj¢ct.
To niake clear, as part of that support. the cxpeclalions of the Foundation.
To SLI goals as to rLporting against outpul5.
To receive Projecl updates and carry out inspections.
To learn from experience and maxiinise future support in achieving public benefit ai)d the foundation's goals.
Beneficiaries are required to report to the Foundation on an interim b￿15 and at tlie end of their appl icable funding period. SLich
reports typically summarise the activities underlaken and include details of Éh¢ ¢nd-users who have beiiefitted froin the
activitieslpt'ojects. In addition, testimonials from b¢iicficiaries also indicate the difference which the Foiindation's graiit-making
activities have had on both individual beneficiaries and at a societal level.
Public Benefit Statement
The public benefit requirement is dcfined in the Charities Act (Northern Ircland) 2008 and states that purposcs must bc for the
public benefit to be charitable. The Trustecs confim tl)al Ihey have complied with thc duty to have regard to the guidance
issued by the Charity Commission for Northern Ireland under section 4(b) of th¢ Charities Act (tlie public bciiefil requircinenl
statutory guidaTice). The 'fnJste¥s arl Confident that the activities liave lielped to achieve the Charity's purposes and provide a
benefit to the beneficiaries.
Financial review
Duriiig the year donations of £500,000 (2022.. £Nil) were received froii) subsidiaries of Almac C7roiip, at)d direct cliaritsble
expenditure of £617,668 (2022.. £833,128) was incun'ed by Ilie cliarity, as disclosed iii iiotc 5. Nel oulgoiiig re8ourLLS for thL year
amounted to £650,075 (2022.. £860,020). The cliaritable conipany's net assets are £91,033,578 (2022 as reslatcd.. £91,167,127).
I'he Trustees are satisfied that the outcome is in line with tlie cliarity's planned expeiidilurc oli prajeets which tl)ey have decided
to fund over a p¢i'iod of several yea15 to enable the aiins of cach proj¢¢t wiiliin each strategic focus ared to be achieved. I'he
Trustees are considering future funding requireinents on an ongoing basi5,
Reserves policy
I'lic l ivstees have establislied a policy w5)ereby tlie free reserves l)eld by tl)e chariiy sliould Inatcli ILS needs. botli at the current tllne
and in Il)e foreseeable futiire. After making allowances for rcstrictcd funds, designated funds, and tlie carying amoiint of functioiial
assets, the charity had free reserves of £523,578 (2022= £657,127). The fyee reserves required will be suificieni to meet the running
costs for a period eqiiivalent to approximately 12 months of expendiiiire. Tiiis policy is reviewed annually. Ilie Board of Trusiee.%
will continue to monitor tlie reseives position and movcment in reserves in line witli Uic policy lo ensure tliere is no iin1nediate risk.

The Mcclay Foundation
(a company limited by guarantee)
13
Trustees, report for the year ended 30 September 2023 (incorporating the Director's
report) (continued)
Inv¢stinenl policy
The Trustees have tlie power to invesl in such as.sels as they see fil, subject to tlie cliarity's Articles of Associalion. Proposed
investinenls iiiust be tabled for r¢view 4nd approval al a Ineeting of the board of 1'ru.%tees.
Taxation stalu5
The Mcclay l.'oundation is a rcgislcred charity. and as such is enlilled lo certain lax excmplions on income and profits from
investinellts, and surpluses oil any trading activities cari'ied on in fuitl)erance of tlie charily's priinary objectives, if tl)ese profils
and Surpluses are applied solely for ch<iritable purposes.
The charity is not registered for VAT and accordingly, all its expenditure is recorded inclusive of any VA T incurred.
Plans for future periods
The Trnstecs, plans for the future are fociised on delivering the cliaritable obligations which al'e d¢Éail¢d in the foundation, s
choseii Strategic focus areas. Tlie Trustees havu decid¢d to fund chosen projects for an appi'opriale niiinber of years tu ¢illow
the inaximuiii d¢gr¢e of planiiing and implLmciilatioii for sucli projects to ei)able thein to acl)i¥vc the most beneficial impact.
Going concern
The cliarity's forecasts and pr()jections, lakiTig account of reasonable possibl¢ changes in perfomiance, show that the use of the
going concem basis of accounting was considered appropriate belau.se th¢r¢ arl no Inaterial uncertainties relal¢d (o events or
coiiditioiis that may cast stgiiificat)I doubt about the ability of tlie charity to continue as a going concern.
Funds lield as custodian trustee on behalf of others
There are no funds held as eustodian trust¢¢ on behalf of others.
Statement of Trustees, responsibilities
Ilic Tru4tees (wlio are al%ii dirLL'li)r% of Th¢ McCll4 y Foi)i)(l(Ition for the purposes of company law} are responsible for
prLparirig Llie Trustccs, Annuul RLport and IhL finai)Lial stateineiits in accordance with applicable law and regulation.
Company law r¢quires ilie Trustee5 to prepare financial sl4t¢ments for each financial year. Under that law the I'rusteos have
pr¢par¢d the financial statements in accordance with United Kingdom Accounting Standards, coniprising FRS 102 "TIIL
F inancial Reporting ,Standard applicable in the UK and Republic of Ireland" aiid applicable law (United Kiiigdoin Cjcncrally
Ac¢ept¢d Accounting E)raciice). Uiider company law tl)e Truste¢s inu8l not approve tlie finaiicial 5tateiy]ent% uiilL'ss IhLy dre
satisfied that they give a ti-ue and fair view of the statc of th¢ affairs of tlie charitable coinpany and of ihc incoming resources
and application of resources, including the income and expenditure, of the charitable company for thal period. In preparing
tl)ese financial statements, the Trust¢es ar¢ r¢quired io:
select suitable accoiinting policies and tl)en apply thein ¢onsist¢ntly;
observe tlie iiiethods and principles in the Statement of Recoinmlnded Practice: Accountiiig and Reporting by
Charities (2019).
make judgments and estiinates that are reasonable and prudent;
state wliether applicable UK Accoiiniing Standards, comprisin&F I". RS 102, hav¢ been followed, subject to any Inat¢rial
departures disclosed and explained in the financial statements. aiid
prepare the financial stateinents ()n the go3ng concei'n basis unles5 tt is inappropriat¢ to presuine thal the charitable
coinpany will conlinu¢ Én busines.s.
'R'lie I rustees ar¢ r¢sponsible for keeping adequate accountino r¢cords that are %ufficient to show and explain the charithble
conipany's trantsactions and disclose M'ith reasonable accui'acy at dn}2 tiii)e the financial position of the charitablL company dnd
eiiable them to ensure that the financial statements coinply willi the Companics Act 2006. Tliey al'e also responsible for
safeguardino the assets of thL' chai-ilable compaiiy and hence for taking rLasonable steps for the prevention and detcction of
fraud and oth¢i' irregularitie%.

The Mcclay Foundation
(a company limited by guarantee)
14
Trustees, report for the year ended 30 September 2023 (incorporating the Director's
report) (continued)
Statement of disclosure of information to auditors
So far as each of Éhe Trust¢cs in office al tlie dale of approval of thcs¢ financial slalcmeiils is aware:
there is no relevani audit information of wliicli the charitable company's auditors is unaware; and
they have tak¢n all the steps that they ought to have taken as Triistees in order to make Iheiiiselves aware of any relevant
audil information ai)d to establisli that the cl)aritabl¢ company's auditors at'e aware of that irifomiation.
Small companies, exemption
This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of tlie
Coinpaiiies Act 2006.
Independent auditors
The auditors, Pricewaterhousecoopers LLP, have indicaled their willingness to continutt in office. and a resolution concerning
their reappointmcnt will be proposed at the Annual General Meeting.
This report was approved by the board of Trustees and signed on its behalf.
A D Annstrong
Trustee
26 January 2024

The Mcclay Foundation
(a company limxted by guarantee)
15
Independent auditors, report to the members of The Mcclay Foundation
Report on the audit of the financial statements
Opinion
In ouropinion, The Mcclay Follndxtion's finaneial statements (the°financial statements.):
gil'e a true and fair Niew of the state of the charitable conipan}Os affairs as at 30 September 2023 and of its inconiing
resources and application of resources, including its income and expenditure, and cash flolis for the)"ear then ended;
have been properly prepa￿1 in aeeordance ￿ryth United Kingdom Generally Accepted Ace0￿ntIng Practice (United
Kingdom Aecounting Staiidards, including FRS 102"The Financial Reporting Stsndard applicable in the UK and
Republic of Irelond", and applicable laiv)" and
have been prepored in accordance ￿1th the requirements of the Companies Aet 2006.
We haN'e audited the finai)cial statements, included M'ithin the Annual report and financial statements (the "Annual Report"),
M,hieh coinprise: tlye balanee sheet as at 30 .%eptember 2023; tlie slatement of finaneial acti14ties (incorporating dil incoiiie aiid
expendilure account), and cash flom, statement for the year then ended; and the notes to the financial statements, ii,hich include
a description of significaiit accounting polici&s.
Basis for opinion
We eonducied our audit in accordance fvryth International Standards on Auditing (UK) ("ISk8 (UK)"} and applicable laiv. Our
responsibilities under ISA8 (UK) are further deseribed iii tlie Auditors, responsibilities for the audit of tlic fiIiai)cial stateinents
section of our report. We beliei'e that the audit ￿Idence w'e have obtained is suffioient and appropriate to pryJN'ide a basis for
our opinion.
Independence
We remHined Inde￿ndent of the charitable compan), in accordance Mith the ethical requirements that are relevaiit lo our audit
of ihe fillaiicial statements in the UK, M'hich includes the FRC'S Ethical Standard and M'e liai'e fulfilled our other ethical
responsibilities in accordante i¥iih these requirenients.
Conclusions relating to %oing concern
Based on the M'ork li'e hai'e perfornied, we hai'e not identified an}, material iincertainties relating to ei'ents or conditions that,
indii'iduall) or eollectivel),, ma}, casl sigiiifjeai)t doubt on the charitable company's abilit>, to continue as a goins concern for a
period of at least hfytli'e months from the date on whieli the financial statements are authorised for issue.
In audiling the financial slatci)ients, i%'e haip coneliided tliat the trustees, use of the going concern bAsis of accounting in the
preparntion of the finaiieial statemellt5 is appropriate.
HoW￿,er, because not all future eNents or covjdilioiis can be predicted, this conclusion is not 8 guarantee as to the charitable
coinpaii} s abilil}' lo contiiiue. as a 8Ding concern.
Our responsibililies and the ￿pOnsibIlitieS of the trustees wTrth Tespeet to going concern are described in the relevant sections
of this report.
Reporting on other infomation
The oiher information comprises all of the infomiation in the Annu31 Report other than the financial statements and our
&iiditors' report thereon, The triislees are rcsponsible foT the other inforniation. Our opinion on the fInanci¢l1 statements does
not coi'er the other infonnalion and, accordinglv. we do not express an alldit opinion or, except to the extent othenyise
explicitls. stated in this report, any fi)rm of assuranc￿ thereon,
In Connection ￿Trth our audit of the financial statements, our responsibilit). is to read the other infonnation and, in doing so,
consider M'hether the other information is materially inconsistent iiith the financial statements or our knioi¥ledge obtained in
the audit. or othenlise appea￿ to be materialls. misstated. If li'e identify, an apparent material illconsistenc}' or material
misstatement, we are required to perform procedur&8 to conelude ii'hether there is a material M￿latement of ihe financial
statements or a material misstatement of the other informntion. If, based on the ii'ork lie hai'e performed, lie conclude that
there is a vnaterial misstatement olthis other information, li'e are required to report that fact. Mfe haNe nothing to report based
011 th￿ responsibilities.
Tith respect to the Trustees, report, lie also considered w'hether the diselosures requÉred b) the UK Companies Act 2006 aThd
Charities Act (Northern Ireltsnd) 2008 hal'e been included.

The Mcclay Foundation
(a company limited by guarantee)
16
Independent auditors, report to the members of The Meclay
Foundation (continued)
Reporting on other Inforn￿tion (Continued)
Based on our work undertakeTh in the Course of the audtt, the Companies Act 2006 requires us also to report ￿rta1Th opinions
and matters as described belom,.
Th￿tee$, report
In our opinion, based on the w'ork undertaken in the course of the audit the inforniation gii'en the Trustees, retnrt for the
period ended 30 September 2023 is eonsistent ilryth the financial ststements. and the Trustees, Annual Report has been
prepared in accordance ivith applicable legal requirements.
In light of the knom'ledge and understanding of the charitable company and its environmeiit obtained in the e0u￿e of the audit,
M'e did not identify an). material misstatement8 in the Trustee5' report.
Responsibilities for the financial statements and the Audit
Responsibilities of the trusteesfor thefinancial statements
As explained more fully in the Slatement of Trustees, Responsibilities, the trustees (w'ho are also the directo￿ of the charitable
coiiipai)J' for ihe purposes of c'onipan) law) are responsible for the prepaTalion of the finai)L'ial siateineiits in aecordanee with
the applieable framework and for being satisfied that they sii'e a true and fair iryew. The trustoes are also responsible for such
internal control as the), determine is necessaT)' to enable tlie preparalion of financial slatemeiits that are free froni niaterial
misstatement, M'hether due to fraud orertr)r.
In preparing the financial Statements, Ihe trustees AIE responsible for assessing the eharitahle compan} s ability to eoiilinue as a
going concern, diselosing a5 applicable, matters related to going concern and using the goin8 concern basis of accountiiig unless
the trLlStees either intei)d lo liquidate the charitable eompany or to cease operations, or hai'e no realistic alteri)atii'e but to do so.
Auditors, responsibilitiesfor the audit of thefinancial statements
Our objeeti1￿ are to obtain Teasonable assurance about whether the financial statements as a M'hole are free from material
niisstatement, M,hether due lo fraud or ei'roi,, and to issue an auditors, report that includes our opinion. Reasonable assurance is
a high I￿,el of assuranec. but is not a guarantee that an audit conducted in accordance Mqili IS￿% (UK) Mill alwa}'s deteet a
malerial n)isstalenient M'hen it exists. Mi&8tatements exn arise. from fraud or error and are considered material if, indiiiduall}' or
in the aggregate. they could reasonabl}, be expected to influence the economie decisions of users taken on the basis of these
financial statements.
Irre8ularities, tneludins fraud. are instLnces of non-compliance witli laws and regulations. We design procedures in line Mith
our re.qponsibilities, outlined abm'e, to dcleet material misstateme.nts in respcct of irregiilarities. including fraud. The exteiit lo
which our pri)eedU￿S are cthpable of delecting irregularities, including frdud, is detsiled below.
Based oil our uilde￿laI1dIllg of the charitable eompaiiy and ils eniir()nment, ive identified that the prii)cipal risks of non-
compliaiice with laii's and re.gulMtions related to Cliarities Ac.t (Northern Ireldnd) 2008 aiid we coi)sidcr¢d the extent to which
non-compliance might have a material effect on Ihe. fiiianeial 8tatements. We also LY)nsidcrcd those laws and regulations that
hai'e a direct impael on Ihe. financial slatements suLh at> ihe Coii)paiii(s A¢t 2006. We evaluated manxgement's inceiitii'es and
opportunities for fraudulent manipulatlOlL o( thL fiiiaiicial statcnients (including the risk of oi'e.rri(le of contn)ls), and
detemiined that the principal risks w'ere related to the posting of inappropriate journal entries. Audit procedures performed
included:
Enquiry, of niaiiagement and the board of trustees. including consideration of known or suspected instances pf non-
compliance ii'ith lams and re8ulations and fraud.,
Reading minutes of meetings of the board oftnjstees;
Understanding and ￿'a]VatIng thecharitable company's control eniironiT]ent',
Idelltif)ing and testins journal entries. including journal entries posted M'ith unusual aecount e()mbinations to income
or expenditure accounts" and
Assessing financial Statements disclosures. and testing to supporting documentxtion, for complian￿ ikith applleable
laws and regulations.

The Mcclay Foundation
(a company limited by guarantee)
17
Independent auditors, report to the members of The Mcclay
Foundation (contmnued)
Responsibilities for the financia] statements and the audit (contlnued)
There are inherent limitations in tILe audit procedures described abost. We are less likel> to become aware of illstan￿ of non-
eompliance with laii's arAd regulatioiis that are not closel) related to ei'ents and transactions reflected in financixl statements.
Also. the risk of not deteeting a material n)isststeTnÈnt due to fraud is higher than the risk of not detecting one ￿ultIng from
error, as fraud ma), involi'e deliberAte conee21ment bs,. for example, forgery, or intentional misrepresentation5 or through
collusion.
Afurther description of our responsiliilities for the audit of the financial staternents is located on the FRC'S website at:
Mwi'.frc.org.uk1audito￿respo￿5ibIll11É.5. This description fornis part of our auditors, report.
Use of this report
This report, including the opinions, has been p￿pared for and only for the charitable company's members as a b(K]y in
accordaiice i¥ith Chapter 3 of Part 16 of the Companies Ael 2006 Rnd (or no othcT purpose. We do not, in giiryng these opinions,
acce.pt or as8unie respon5ibilit)' foT Jny uther piirposc or to any other person to whom this report is sliown or inlo whose hands
it ma) come Sill'e where expiessly agreed b), oui. prior eonsenl in writing.
Other required reporting
Companies Act 2006 exception reporting
Under ihe Companies Act 2006 Me are required to report to you if, in our opinion:
we ha%'e not obtained all the information and explanations we require forour audit., or
adequate accountiils Tecords hai'e not been kept by the charitable company or returiis adequate for our audit hai'e
not been re￿I%,ed from branches not i'isited by us; or
certAin disclosures of trustees, remuneration specified b}, laii, are not made. or
the charitable compan> financial slalements are not in agreement with the accounting records and ￿turns.
We l)ai'e no exceptions to report arising from this responsibility.
Entitlement to exemptions
Under the Companies Act 2006 ile are required to report to }'ou if, in our opinioii, the trustees were not entitled lo: prepare
financial statements in accordance iiith the sniall eompanie5' regime; tske adi'antage of the small conipanies, exemption in
prepariii8 tlie'l'ruste&g' report; and lukL adi'uiilage. ol thc.8mllll eompani&s exemptioii fr()m preparing a Strntegie Report. Wc
no exceptions to report arising from this responsibility,
Emma Murray (Senior Statulory Auditor)
forand on behalfof Priceii-aterhousecoopers LLP
Chartered Aceountants and Statutory, Aiiditi)rs
Belfast
6 Februaryy 2024

The Mcclay Foundation
(a company limited by guarantee)
18
Statement of financial Activities (incorporating income and expenditure account) for
the year ended 30 September 2023
Total
Uiirestricted
funds
2023
Unrestricted
runds
2022
Note
Incoming resources from generkttd fun(Is
Investin¢nt incoine
16,526
500,000
516,526
10,202
20,000
30,202
Donations
Tolal incoming resourees
Resources expendcd
Charitable activities
(637,668)
(12,407)
{650,075)
(133,549)
{833.128)
(26,892)
(860,020)
(829,818)
Cyovernance costs
Total resource5 expended
Net expeilditure 8nd net movement in funds before gains and
losses on investinents
Net gAins on investment property assets
Net expenditure and net Inovement in funds
Totol funds brought forward at l October
Total funds earried forward at 30 September
10,000
(819,818)
91,986,945
91,167,127
(133,549)
91,167,127
91,033,578
The slatcmenl of financial activities includes all g8ins and losses r¢cogniscd in the year. All incoine and expenditiire derive
rroin coiilinuing activities.

The Mcclay Foundation
(a company limited by guarantee)
19
Balance sheet as at 30 September 2023
2023
2022
Note
Fixcd assets
Iiiveslmenls
90JOO,000
210,000
90,510,000
90,300,000
210,000
90,510,000
Inveslinenl property
10
Current Hssets
Debtor5.' ainounts falling due within one year
Cash at bank and in hand
870
580,238
714,059
714.059
(56,932)
657,127
91,167,127
581,108
{57,530)
523,578
91,033,578
Creditors: amounts falling due within one year
Net current a￿setS
12
Net assets
The funds of the charity:
Unrestricted funds
91,033,578
91,033,578
91.167.127
91,167.127
Total eharity funds
I'he financial statements on pages 18 lo 29 were approved by the board of Trust¢¢s on 26 January 2024 and were signed on its
behalf by:
A D Armstrong
Trustee
I W Fliiddleston
Triislee
1.he noles on pagcs 21 to 29 are an integral part of the financial staieinents.
The Mcclay Fouiidxtion
Registered numb¢r: N1070062

The Mcclay Foundation
(a company limited by guarantee)
20
Cash flow statement for the year ended 30 September 2023
2023
2022
Note
Cash tlows from operating activities
Net casli uscd in upei'ating activities
Net decrease in cash and exsh equivalents
Cash and cash equivalents at beginning of the year
Cash and cash equivalcnts at end of the year
14
{133,821)
(133,821}
714,059
580,238
(8?3.319)
(823,319)
1,537,378
714,059
The notes on pages 2110 29 are an integral part of ihe financial staleinents.

The Mcclay Foundation
(a company limited by guarantee)
21
Notes to the financial statements for the year ended 30 September 2023
Accounting policies
General information
Th¢ nalur¢ ofThe Mcclay E."oundalion is tliat of a charity, Thc Foundations objectives are, broadly io..
Support and ¢n¢ourag¢ rcsearch and innovation
Advance the usc of diagnostic 10015 and drugs in the pi'evention, conlr()l and cure of disease
.nsui'e lat¢%t advances in liealthcare available to all, including developing cotintri¢s
Cieneratc and promote einployment opportunities
Support and pi'oinote such educational putyoscs as tli¢ Irustces tshall ,select, provided that such purposes ghall be exclusively
Charilablc in law
I"he charity 1% in¢()rporated in the United Kingdom and is r¢gistered in Noi1hern I￿land. The address of its registered orrioe is
AlinaL Elous¢, 20 Seagoe Industrial I:state, Craigavon. B T63 5QD.
Statement of compliancc
The individual financial stateirents of I"he Mcclay Foundation hav¢ been prepared in compliance with Accoiinting and
Reporting by Chai'itie5.' Statemei)t of Recominended Practic¢ (8ORP), l.Inile(l Kiiigdoill Accounting Standdi-d5 inclliding
rinancial Reporting Standard 102, the Coinpanies Act 2006 and the Charities Act (Northern Ireland) 2008.
B&sis of preparalion
The financial stalements have been prepared on a going concern basis, under the historic c05t convention, and in accordance WTth
Accounting and Reporting by Charities: Sialeinent of Recomm¢nd¢d Practice (SORP) applicable to charities preparing their
financial stateincnts in accordance with the F inancial Reporting %tandard applicable in the UK and Republic of Ireland (fRS
102) effeclive l January 2015), (Cl)arities SORP (FRS 102)), th¢ Financial Reporting Standard applicabl¢ in the UK and Republic
of Ircland (FRS 102), the Charities Act (Noithem Ireland) 2008 and the Companies Act 2006.
The preparation of the financial slateinents requires the use of certain crilical accounting estimates. It also requires manag¢menl
to exercise its judgen)er)t in tl)e process of applyiiig the group and charity ¢iLcountin& policies. Manageinent has concluded Ihat
there ore no criticttl assumptions, estimates or judgements involving a high degree of jiidgement or complexity which I'equire
further disclosui'e as outlined in note 2,
I'lie principal accounting policies, which have been applied consistently ihroughoiil the year, are set oui below,
Con501idation
Tlle Mcclay l.oundation owns 990/0 of the ()rdindry A share capital and IOOO/o ofthe Ordinary B share capilal of Almac Group
l.iillited. lhe shal'e capital structure of Almdc Group l.imited also includes a £ I founder shal'e which lia5 veto rights in a nuinber
of areas. UndLr Lharity law, tlie Foundatioii is regardcd a5 the conlroller of Almac (yroup Liii)iled which, as a subsidiary of the
roiindation, delivers tlie Foundation's chai'itable purposes. Alihoiigh die l-"oundation is the beneficial owner of Alinac (rl'OUP
I,iiMited, tlie Trustees do not exercise conlrol for Ilie purpose of Section 401 orth¢ Coinpanies Act 2006. 1'he financial stateinenl8
Ilierefore present infor]t)ation about tlie coinpany as an individual undertaking.
Investments
Investnicnls in associates Ètre held as non current assets and ar¢ held at ¢osl Icss accumulated impairment losses, An iJnpairinLnl
loss is recognised for 11)e aii)ouiit by wliich the &sset'.s canying ainouni exceeds its recoverable amount.
Investment properties
Investment properties for ivhich fair value Lan be nieasured reliably is measured at fair value annudlly with any change recognised
in the statemei)t of financial aLtiviliL'%.
Debtors
Debiors are initially stated at cost and subsequently staled after all known bad debts have beLn writteF] off and specific provision
has been inade against all debts considei'ed doiLbifiil of collection.

The Mcclay Foundation
(a company limited by guarantee)
22
Notes to the financial statements for the year ended 30 September 2023 (eontinued)
Accounting polieies (continued)
Incomiiig resource5
All incoining resourc¢s consist of volunlary incoine and inveslinent income and are included in the st8teinent of financial
activities when ihe charity is IL'gally entitled to tlie incoine and the ainount can be quantified with reasonable a¢¢uracy.
Voluntary Èncome
VolLSnlary incoine is incoinc which is received by way of donalioi)s and gift.s lo Ihe charity and is included in full iii the slaleinent
of financial activilies when received.
Investment Inconie
Bank int¢resl and loan interest receivable is included in full in the statement of financial activlties on an accruals basis.
Rental tncome
Rental income is included in fijll in the stateinenl uf financial activities on an accruals basis.
Poliey for the awarding of grants
The Fouiidation's grani programmes are approved by Trustees. The Foundation will only accept applications froin registered
charilies. All programmes involve an application pro¢¢,qs. Applications are assessed by the Truslees, incliiding robust
assessment of governance. F iiial approval is sougl)t at board meeting5, before decisions are sharcd with applicants. 'I'he
appliCa￿t'S must sign up to Terins & Conditions before funding is released via bacs payment. All grantees must complete an
evaluation report, outlining exper)diture, perforniance, and iinpact on at least an annual basis.
Resources expended
Expenditure is accounted for on an accruals basis and has been classified under headings thal aggregate all costs related to Ihe
category. fxpenditur¢ relates to Charitable Activities and Governance costs which arc outlined below.
Chayitable aetivSties
Cliai'itablc expL'iiditure Ll)Inpri.4L8 th(is¢ cost8 inciirre(I by the cliarily in the delivery of its activilies and services for its
bciicl Iciaries. ThL%L inclu(IL ()llL()logy research, research led care for those in end of life or life liit]iting activities and activities
to pr()IllL)te hLalih dnd wLllbLiiiL? iii di%ci)frai)chised cominunilies and g¢ographiLal areas in the developed and the developing
world. Charitable aclivilies are both costs that can be allocated directly to such activities and those cost5 of an indirect natur¢
necessary to supply Ihcm.
Governance costs
overnanLe Losts are costs associated with general charity advice and governance matters and include those costs incurred in
the goveimancc of its assets wliich are associated with conslitutional and statutory requirements,
Unre8tYteted fund.q
Unrestri¢ted funds are donations and other incoming r¢source% received or gienerated which air expendablc at ihe discretion of
the charity in furtherance of Èts objectives.
Casli and cash equivalents
Cash and cash equivalcnts include cash in hand, deposits held at call with banks. oohei- shori-term Iiighly liqiiid inv¢5tiMcnts
with oi'iginal maluritics ofthree illoiitlis oi. less and bank overdrafis. Bank OVLrdrafts, Ivlien applicable, are showi) within
borrowings in currenl liabilitie5. Deposits with oi'iLyinal inaturities of great¢r than 3 1)ionths al'e shown as cuiyent a%8et oi. fExed
asset investinenLs depending on the date of tnalurity.

The Mcclay Foundation
(a company limited by guarantee)
23
Notes to the financial statements for the year ended 30 September 2023 (continued)
Accounting policies (continued)
Financial instruments
A financial instruiiient is dny contract that gives rise to a finai)cial asset of 01)e party and a financidl liabilily or eqiiiiy inslruinent
f ariother paity. The charity has chosei) to adopt Sections I l and 12 of ]-. RS 102 in respect of financial in%truiiienls which sets
oul the requireinents for the rccognition, derecogiiilion, Ineasurement and disclosure of financial as%els and fiiiancial liabilities
Finanei218ssets
E", inancial assels. including trade and other debiors and ca8h and bank balances, are inilially recognised at transaction pi'ice,
unless the arrangemeiit constilute.% a finaiicing ti'ansactioii, where the transaction is measured at the present value of the fiitui'e
receipts discounted at a market rate of interest.
Such assets arc subsequently carried at amortised cost using the effective interest imethod,
At the end of each i'cporting period financial assets measurLd (It amortised cost are asscssld for objLLtive L'vidence or
impairn)enl. If an asset is iillpaired tlie iiiipairinent loss is th¢ dillerei)ce between the carrying amount and ihc present value of
the estimaied cash flows discounted at the asset's original effective iiiterest rate. I'he inipairm¢nt loss is recogn i%ed iii th e
Statement of financiHI activities.
If there is a decrcase in the impainnenl loss arising from an event occurring after the iinpairment was recognised the
impainrjeni is reversed. The reversal is such that the curi'ent currying ainounl does nol cx¢e¢d what the carrying amount would
have been had the iixpairn]ent not previoiisly been recognised. Thc impairment reversal 15 recogni5¢d in ihe Stateinenl of
financial aclivilies.
Other financial assets, including investments in equity instruments which are nol subsidiaries, associates, or joint ventures, are
initially measured at fair value. The quoted market value is used to detemine fair value.
Such assets are subsequently carricd at fair value and the changes in fair value are recognised in profit oi'1088, except that
investillei)Is in equity instruinents that are not publicly traded aiid who8e fair values cann()t be mea%ured reli<ibly are measured
al cost less kmpairment,
FiE)ancial asset5 arc d¢recognised wheil (i) tl)e contractual rights to the casli flows from the assel expii'e or are settled, or (li)
sub5tantTally all the risks and i'ewards of ihe owiiei'sliip of the asset are transferred to an()Iher party, or (iii) control of the asset
has been transferred to another party who has the practical ability to unilotcrally sell the asset lo an unrelated third party
without imposing additional i'estrictions.
Financial liabilities
F.. inancial liabiliti¢s, incliiding trade and other creditors, bank overdiyfts and other loans, are initially recognised at transaction
pi'ic¢, iinless the ari'angemeiit coiistitutes a fiiiancing transaction, whei'e the debt insiruinent 15 measured at the pres¢nt value of
the future receipt5 discounted at a imarket rate of intcrcsl.
1.radc ci'edilor5 are obligations to pay for goods or services that have been acquired in the ordinary Course of business from
suppli¢i's. Trade creditors are classified as rurreni liabilities if payment ts due williin one year or less. If not, tliey are
presented as non-cui'rent liabiltties. I rade Creditors are recogyni5ed initially at Iransactioii price aiid subsequently Inea5ured at
ainortised cost using the effective inter¢st method.
l.'inancial liabiliti¢% ar¢ dc'recognised ivhen the liability is extinguished, that is when the contractual obligatio# is discharged,
canccllcd, or expires.

The Mcclay Foundation
(a company limited by guarantee)
24
Notes to the financial statements for the year ended 30 September 2023 (eontinued)
Critical accounting judgements and e$timation uncertainty
F-,81imales and judgements arc coiitiiiually evalualed and are based on historical expcrience and other facioi's, including
expeelations on future even15 that are believed to be I'easonable linder Ihe cir¢uiMstances.
(a) C'rilicaljzldgemenly in applyiy2R ihe cottJpory'.i aecouNlingpolicies
I'here are iio crilical judgeijicnts in applying the company's accounting policies
Crilical accounting eslimaies aiid as.suixplions
There al'e no critical accounting estiinates and assuinptioiis.
Legal status of the charity
The charity is a company limited by guarantee and has no share capital. 'fhe liability of each iiiember in the eveiit of winding-
up is liinited to £ l.
Total incoming resourees
Total
iirestricted
runds
2023
Total
unreslricled
funds
2022
Investment income
Bank interest
8,726
7,800
16,526
2,402
7,800
10,202
Rental in¢oin¢
Donations
Donations from All￿aC Group
Donations - oth¢r
500,000
20.000
30,202
516,526

The Mcclay Foundation
(a company limited by guarantee)
25
Notes to the financial statements for the year ended 30 September 2023
Charitable activities
Total
unrestricted
funds
2023
"rotal
unrestricted
fund5
2022
Queeii's University BclftLSt
Nortl)¢rn Ireland F4ospice
Nl Caiicer fund for Children
151,040
loo,000
147,255
50,000
50,000
70,000
Friends of the Cancer Ccntre
70,000
25,000
100,500
Gel Active
Quesl Malawi
Fields of Lif¢
40.478
67,930
Young L.ives v Cancer
Train to be Smart
25,000
37,720
37,720
16,000
16,838
100,000
Reach
Philadclpliia F.ducation F und
UNICL
15,058
Cope Childrens Thisl
Buddy Bear I'rust
(JO Kids Go
10,000
100,000
100,000
2,000
1,600
82,1184
46.582
2,530
1,311
833,128
Cancer Trocus
Childrei)'s I lospital of Philadelphia
Duke University, North Carolina
Fricnds of Parkview Special School
Marie Keating l oundation
2,750
637,668
Charitable activities ¢oinprise those costs incurred by th¢ chariiy in lh¢ delivery of its activities and scrviccs foi- ils
beneficiaries. Includes oncology I'esearch, research led car¢ fur those ii) end of life or life limiting aLlivilies and activit ies to
proinote health and wellbeing in disenfranchis¢d cominunities and geographical areas in the developed and the developing
world.
(iovernance costs in relation lo professional services in tlie year were £12,407 (2022.. £26,892).

The Mcclay Follndation
(a company limited by guarantee)
26
Notes to the financial statements for the year ended 30 September 2023
Movement in funds
2023
2022
The net movement in fuiids are stated after charging:
Fecs payable to the cliaritable compatiy's auditor8 f()r the aiidit of tlie finaiicial
5tateilleiits
6,000
I mployee information
To date there have been no staff einploy¢d by the ¢hai'itable company and there is no key Inanagement to disclose (2022.. Nil).
I'he Trustees received no re1￿uneratiOn or rcimbursel￿eMt of expeiises in respect of their service%. IndLmiiiiy in8iJrance is in place
ror all Trustees aiid the charge for the ycar ended 30 September 2023 was £6.000 (2022: £6.000).
Taxation
The compony is a registered charity and. as such, is entitled to certain tax excmptions on income and profits froin investmeiils
and surpluses on aiiy trading activitics Larried on in furtherance of the charilablc Company's primary objectives, if ihese pi'ofits
and surpluses are applied solely for charitable purposes.
Investments
Investment in
associate
Al l Octobei. 2022 and 30 SeptCTnber 2023
90,300,000
During tlie year ended 30 Septeniber 2009, Dr Sir Allen Mcclay gifted 961,538 'B' ordinary shares in Alimac LT¥OUP Limited to
Tlie Mcclay Foundation.
l)uring the year ending 30 September 2012 the b.xecuÈors of the estoÉe of Dr Sir Allen Mcclay gifted 657,327'B' ordinary shares
in Almac (proup l.imited to The Mcclay Foundation.
During the year ending 30 8¢ptember 2014 the trustees of th¢ Allen J. Mcclay (Almac) Discreiionary Scitl¢inent gifted
13,286,028 'A' ordinary sl)ai'es in Almac Group l.iniited to Tlie Mcclay Foundation.
During Ihe year ending 30 Septeinber 2014, th¢ trustees uf The Allen J. Mcclay Settleimenl gifted 142,718 'E3' ordinary sharcs
in Alinac GroLlP l.imited to I'he Mcclay l."oundation.
During the year ending 30 Septeinber 2017, tli¢ tru.8t¢¢s of The Allen J. Mcclay Seltleinent gifted 78,207 'A' ordinary sliareq iii
Almac Groiip l.imited to I'he M¢Clay Foundation.
During the year ending 30 Sept¢mb¢r 2018, the trustees of The All¢n J. Mcclay Settlemenl gifted 8,523 'A' ordinary %l)ares in
Alinac (iroup l.iinited to 11)¢ M¢Clay F'ouiidatioR.
l)uTing ilie year ending 30 Sepiember 2019, the trustees of The Allen J. Mcclay Settlement gifted 5,750 ' A, ardiiiary sliares in
Almac (iroup l.iiniicd to I'he Mcclay Foundation.
Tl)e total number of "A,: ordiiiary sl)ar¢s noiv oi¥'ned }% 13,378,508 and the total i)unibei- of "B" ordinary s])ares now owiied 18
1,761,583.

The Mcclay Foundation
(a company limited by guarantee)
27
Notes to the financial statements for the year ended 30 September 2023
Investments (continued)
Ilie cliaritable company's associated iindertaking is..
Owneyship
Share Class
Name
Country of incorporatio
Associated undertaking
Alinae Group Liinil¢d
Northern Ireland
990/0
I OOO/o
'A' Ordinary sharcs ()f £1 cach
'B' Ordina
shares of £ l each
Tlie principal activities of Alinac Group l.imited extend fyoin drug discovery through all areas of ¢linical Irials to the
cominercialisalion of phariiiaceutical products. "rhe group providcs world-class integi'ated research and developimenl support
and an unparalleled range of services to custoimers, including the market leaders, within the pharinaceutical and biotL'Lhnology
sectors. The aggregate capital and I'eserves aiid results of the eoinpai)y's associaled undcrtakiiig for ihe yeai. were;
2023
2022
Capital and reserves
Almac Group l.imiied
Profit for the year
Alinac Group Limiled
718,195,917
652,596,962
79,950,443
77,570,937
Thc trustees are satisfied that the carrying value of invcstments 15 SUPPOrted by their undcrlying net assets.
10 Investn)eiit property
nvestmellt
property
A5 1 October 2022 and at 30 S¢ptemb¢r 2023
210,000
uring ihe year ended 30 Septeinber 2022 lh¢ property was revalued on a fair value ba%is 85 at 30 September in accordance
with the charities accounting policy by independenl external valuers at a value of £210,000 resulting in an incrcase in fair value
of £10,000.
I l Debtors: amounts falling due within one year
2023
2022
Prepayments
870
12 Creditors: amounts fallin% due within one year
2023
2022
Accrualts
57,530
56,932

The Mcclay Foundation
(a company limited by guarantee)
28
Notes to the financial statements for the year ended 30 Septem ber 2023
13 Financial instruments
2023
2022
Financial liabilities held at amortised cost
Accruals
57,530
56,932
14
Reconciliation of net movement in funds to net cash flow from operating activitRes
2023
2022
Net movemeiit in funds
(133,549)
(819.818)
(10,ooo}
817
Gain on investinent propcrty
Moveinent in debtors
(870)
598
Movement in creditors
5,682
(823,319)
Net cash used in operating activities
(133,821)
Net fundsl(debt) reeonciligtion as at 30 September 2023
Cash at bank and
in hand
As at l Oclober 2021
1,537,378
(823,319)
714,059
(133,821)
580,238
Cash flows
As al 30 September 2022
Cash flows
As at 30 September 2023
15
Unrestricted fund5
Total
unrestricted
rund5
2023
Total
uiire5tricted
fiinds
2022
At l Octob¢r
91,167,127
91,986,945
Net movement in fund5
(133,549)
91,03J,578
(819,818)
91,167,127
At 30 Scptcmber

The Mcclay Foundation
(a company Ilmited by guarantee)
29
Notes to the financial statements for the year ended 30 September 2023
16 Analysis of net assets between funds
Total
unrestricted
runds
2023
Total
unrestricted
funds
2022
Fixed assets
90,510,000
523,578
91,033,578
90,510,000
657,127
91,167,127
Net cui-i-ent assets
At JO September
17 Ultimate controlling party
The Eloard of Trustees are the ultimate oontrolling party.
18
Related party transactions
Almac (iroup l.imited is a related party through coinmon directors. Donations of £500,000 (2022: £Nil) were received from
subsidiaries of Almac Group during the yeai..
19 Contingent liabilities
At the year end tlie charity had contingent liabilities of:
2023
2022
Nl Flospice
Nl Cancer Fund for Children
Fields of I,ife
Philadelpliia I,:ducation l.-und
Train to Be Sinait
Buddy l)ear Trust
Train to bL Sinart - pledge
QUB.. Mcclay Lhaii's in Mediciiial Cheinistry/Oncology
Young l.ives v Cancer
Children in N()rthern Ireland
Friends of Ihe Cancer Centre
200,000
loo,000
200,000
16,615
37,720
3UO,000
330,000
358,917
50,000
25,000
70,000
1,688,252
50,000
100,000
300,000
35,563
75,440
400,000
431,046
50,000
140,000
1,582,049
The above contingent liabilities represent grant5 coininitted to projects but are contiJJgent iipon the recipiLnt meeltng specific
ci'iteria kn fiiture years. TherL is no evidence of default on tlie terins applied.